New CEO Kare Schultz is steering Teva Pharmaceutical Industries Limited (NYSE:TEVA) back into the good graces of investors, as the recovering Israeli pharma …
How does Hedge fund guru Dmitry Balyasny’s choice to invest new stakes in Teva Pharmaceutical (NYSE:TEVA) and Synergy Pharmaceuticals (NASDAQ:SGYP) while bumping up …
Can Teva Pharmaceutical (NYSE:TEVA) recover after such a third quarter earnings fall? Mizuho analyst Irina Rivkind Koffler is left asking questions of whether …
Mizuho’s Irina Rivkind Koffler says if TEVA can stabilize its business, it could evade a downgrade to high yield.
Billionaire Israel “Izzy” Englander, who helmed his fortune from humble, Polish immigrant beginnings took a chance on two giants that have played with …
Teva Pharmaceutical (NYSE:TEVA) has a few loose ends untied, from generics pressures to brand drug launches and pipelines that still need to prove …
Cantor’s Louise Chen met with Teva’s team yesterday and still sees reason to be sidelined until generics pricing gets better.
Is Teva Pharmaceutical (NYSE:TEVA) overpriced? For a company that just released a third quarter print, Oppenheimer analyst Derek Archila does not have any …
Unfavorable Teva risk/reward and steep valuation keeps Oppenheimer on the sidelines.
Teva Pharmaceutical (NYSE:TEVA) investors have seen a once strong Israeli pharma giant stumble 71% from its former valuation glory, and some on the …
